dichlororibofuranosylbenzimidazole has been researched along with Carcinoma 256, Walker in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Carcinoma 256, Walker: A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| BenÃtez-Verguizas, J | 1 |
| Esbrit, P | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Carcinoma 256, Walker
| Article | Year |
|---|---|
Proliferative effect of parathyroid hormone-related protein on the hypercalcemic Walker 256 carcinoma cell line.
Topics: 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Animals; Antibodies; Bucladesine; Calcium; Carcinoma | 1994 |